There are 2949 resources available
1816MO - ICES (International Carboplatin Emesis Survey) for the evaluation of the emetogenicity of carboplatin-based chemotherapy – with a focus on nausea. MASCC Antiemetic Study Group survey
Presenter: Teresa Smit
Session: Mini Oral - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1628MO - A new benchmark for designing phase II trials for advanced or metastatic leiomyosarcoma (LMS) patients using progression free survival (PFS) as primary endpoint – an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis
Presenter: Georgios Kantidakis
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1629MO - First-line chemotherapy (CT) in advanced well-differentiated/dedifferentiated liposarcoma (WD/DD LPS): An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis
Presenter: Silvia Stacchiotti
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
808MO - Paclitaxel with or without pazopanib in ovarian cancer patients with relapse during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study
Presenter: Florence Joly Lobbedez
Session: Mini Oral - Gynaecological cancers 1
Resources:
Abstract
Slides
Webcast
813MO - Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial
Presenter: Jean-Sebastien Frenel
Session: Mini Oral - Gynaecological cancers 1
Resources:
Abstract
Slides
Webcast
809MO - Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint)
Presenter: David Cella
Session: Mini Oral - Gynaecological cancers 1
Resources:
Abstract
Slides
Webcast
810MO - Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial
Presenter: Bhavana Pothuri
Session: Mini Oral - Gynaecological cancers 1
Resources:
Abstract
Slides
Webcast
811MO - Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1
Presenter: Susana Banerjee
Session: Mini Oral - Gynaecological cancers 1
Resources:
Abstract
Slides
Webcast
LBA33 - Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high‐grade ovarian carcinoma (HGOC): Final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial
Presenter: Antonio González Martín
Session: Mini Oral - Gynaecological cancers 1
Resources:
Abstract
Slides
Webcast
LBA77 - Anti-SARS-CoV-2 antibody response in patients with cancer and oncology healthcare workers: A multicenter, prospective study
Presenter: Antonio Marra
Session: Mini Oral - SARS-CoV-2 and cancer 1
Resources:
Abstract
Slides
Webcast